388 related articles for article (PubMed ID: 18039096)
1. Von Hippel-Lindau disease.
Kaelin WG
Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
3. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
Kaelin WG
Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
[TBL] [Abstract][Full Text] [Related]
5. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
6. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
7. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
Okumura F; Uematsu K; Byrne SD; Hirano M; Joo-Okumura A; Nishikimi A; Shuin T; Fukui Y; Nakatsukasa K; Kamura T
Mol Cell Biol; 2016 Jun; 36(12):1803-17. PubMed ID: 27090638
[TBL] [Abstract][Full Text] [Related]
8. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.
Calzada MJ
Clin Transl Oncol; 2010 Mar; 12(3):160-5. PubMed ID: 20231120
[TBL] [Abstract][Full Text] [Related]
9. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
10. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
11. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
Iida K; Okimura Y; Takahashi K; Inomata S; Iguchi G; Kaji H; Chihara K
Int J Mol Med; 2004 Mar; 13(3):401-4. PubMed ID: 14767570
[TBL] [Abstract][Full Text] [Related]
12. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
[TBL] [Abstract][Full Text] [Related]
13. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
14. Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome.
Gaal J; van Nederveen FH; Erlic Z; Korpershoek E; Oldenburg R; Boedeker CC; Kontny U; Neumann HP; Dinjens WN; de Krijger RR
J Clin Endocrinol Metab; 2009 Nov; 94(11):4367-71. PubMed ID: 19808854
[TBL] [Abstract][Full Text] [Related]
15. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
Kaelin WG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
[TBL] [Abstract][Full Text] [Related]
16. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
Kapitsinou PP; Haase VH
Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
18. The von hippel-lindau tumor suppressor protein: an update.
Kaelin WG
Methods Enzymol; 2007; 435():371-83. PubMed ID: 17998064
[TBL] [Abstract][Full Text] [Related]
19. Von Hippel-Lindau disease and endocrine tumour susceptibility.
Woodward ER; Maher ER
Endocr Relat Cancer; 2006 Jun; 13(2):415-25. PubMed ID: 16728571
[TBL] [Abstract][Full Text] [Related]
20. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
